ABSTRACT
Systemic mastocytosis is a rare disease which is being better recognized and managed. While the vast majority of patients have indolent disease with variable symptom burden, a small proportion evolve or present with aggressive disease. This may be due to increases in mast cell burden (leukemic, associated with tumour masses) or more commonly due to the presence of an additional hematologic neoplasm (SM-AHN). These patients with advanced systemic mastocytosis have poor outcome; however, recent advances in diagnosis, molecular genetics and treatment have changed the prognostic landscape for this group of patients. In this review we address the most topical questions related to diagnostics, classification, new disease entities, treatment and multiparameter prognostic scoring systems.
Subject(s)
Hematologic Neoplasms , Mastocytosis, Systemic , Myelodysplastic-Myeloproliferative Diseases , Humans , Mastocytosis, Systemic/diagnosis , Mastocytosis, Systemic/genetics , Mastocytosis, Systemic/therapy , Mast Cells/pathology , Hematologic Neoplasms/pathology , PrognosisABSTRACT
We report a novel case of multiple paragangliomas in a patient who was identified with pathogenic variants in both NF1 and SDHD genes. The proband is a man with known familial NF1 disease, diagnosed clinically in childhood. Multiple head and neck paragangliomas (HNPGL) were found during investigations for acute left sided neurological symptoms, in the region of his known plexiform neurofibroma. He was referred for genetic counselling. He underwent surgery to remove a left carotid body tumor (CBT). A pheochromocytoma and paraganglioma gene panel was tested. Blood and HNPGL tumor DNA were analyzed by whole exome sequencing. In addition to the NF1 truncating variant c.5107delA, p.(Ser1703AlafsTer7), the SDHD truncating pathogenic variant c.3G > A, p.(Met1?) was found. Tumor sequencing showed no LOH of SDHD or NF1, but monoallelic loss of 11p15 and 11q12.2-q12.3 was observed. Co-occurrence of pathogenic variants in multiple cancer susceptibility genes is rare but possible, identified by the increased use of panel testing. This is the first description of a patient presenting with NF1 and SDHD dual pathology, with HNPGL development due to SDHD. This case illustrates the central role of genetic sequencing in PPGLs and the strong genotype-phenotype correlations of different genes.
Subject(s)
Germ-Line Mutation/genetics , Head and Neck Neoplasms/genetics , Neurofibromin 1/genetics , Paraganglioma/genetics , Succinate Dehydrogenase/genetics , Adult , Base Sequence , Female , Head and Neck Neoplasms/diagnostic imaging , Humans , Male , Paraganglioma/diagnostic imaging , Paraganglioma/pathology , PedigreeABSTRACT
Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non-relapse mortality rates remain significant. Relapse rates vary between 15 and 25% across retrospective studies and management strategies vary widely, ranging from palliation to adoptive immunotherapy and, in some cases, a second allo-HCT. Moreover, in allo-HCT, there is a higher incidence of poor graft function and graft failure due to splenomegaly and a hostile "pro-inflammatory" marrow niche. The Practice Harmonisation and Guidelines subcommittee of the Chronic Malignancies Working Party (CMWP) of EBMT convened an international panel consisting of transplant haematologists, histopathologists and molecular biologists to propose practical, clinically relevant definitions of graft failure, poor graft function and relapse as well as management strategies following allo-HCT. A systematic approach to molecular monitoring, histopathological assessment and chimerism testing is proposed. These proposed recommendations aim to increase the accuracy and uniformity of reporting and to thereby facilitate the development of more consistent approaches to these challenging issues. In addition, we propose management strategies for these complications.
Subject(s)
Graft Rejection/prevention & control , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Practice Guidelines as Topic/standards , Primary Myelofibrosis/therapy , Disease Management , Graft Rejection/etiology , Graft Rejection/pathology , Graft vs Host Disease/etiology , Graft vs Host Disease/metabolism , Humans , Primary Myelofibrosis/pathology , Recurrence , Transplantation, HomologousABSTRACT
Thyroid cancer therapy is increasingly tailored to patients' risk of recurrence and death, placing renewed importance on pathologic parameters. The International Collaboration on Cancer Reporting (ICCR), an organization promoting evidence-based, internationally agreed-upon standardized pathology data sets, is the ideal conduit for the development of a pathology reporting protocol aimed at improving the care of patients with thyroid carcinomas. An international expert panel reviewed each element of thyroid pathology reporting. Recommendations were made based on the most recent literature and expert opinion.The data set uses the most recent World Health Organization (WHO) classification for the purpose of a more clinically and prognostically relevant nomenclature. One example is the restriction of the term minimally invasive follicular carcinoma to tumors with capsular invasion only. It reinforces the already established criteria for blood vessel invasion adopted by the most recent WHO classification and Armed Forces Institute of Pathology fascicle. It emphasizes the importance of the extent of blood vessel invasion and extrathyroid extension to better stratify patients for appropriate therapy. It is the first data set that requires pathologists to use the more recently recognized prognostically powerful parameters of mitotic activity and tumor necrosis. It highlights the importance of assessing nodal disease volume in predicting the risk of recurrence.The ICCR thyroid data set provides the tools to generate a report that will guide patient treatment in a more rational manner aiming to prevent the undertreatment of threatening malignancies and spare patients with indolent tumors the morbidity of unnecessary therapy. We recommend its routine use internationally for reporting thyroid carcinoma histology.
Subject(s)
Carcinoma/pathology , Neoplasms, Glandular and Epithelial/pathology , Pathology, Clinical/standards , Research Design/standards , Thyroid Neoplasms/pathology , Humans , Neoplasm Recurrence, Local/pathologyABSTRACT
Lymphomas arising in the adrenal are rare, and to our knowledge, 2 cases of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (DLBCL) in an adrenal pseudocyst have been reported. We report an incidental EBV-positive DLBCL arising in an adrenal pseudocyst in a 58-year-old man with a 7-year history of lymphoplasmacytic lymphoma (LPL). The DLBCL was present in the fibrinous exudate, while the LPL resided in the cyst wall. The patient underwent de-roofing of the same cyst 3 years previously; review of histology revealed foci of LPL in the cyst wall, but not of DLBCL. There have been reports of similar microscopic EBV-positive DLBCLs within enclosed cystic spaces. However, all these cases were incidental extranodal primary DLBCLs. Since residual LPL was present alongside DLBCL, with similar light chain restriction, we propose that this may represent transformation, rather than a de novo primary EBV-driven lymphoma.
Subject(s)
Adrenal Gland Neoplasms/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Neoplasms, Multiple Primary/pathology , Waldenstrom Macroglobulinemia/pathology , Epstein-Barr Virus Infections/complications , Humans , Lymphoma, Large B-Cell, Diffuse/virology , Male , Middle AgedABSTRACT
Lymphangiomas are neoplastic lesions derived from lymphatic endothelium. They are largely encountered in the head and neck region. We describe a case of an adrenal lymphangioma, an extremely uncommon cystic lesion of the adrenal and discuss the differential diagnosis, clinical, imaging, histopathologic and immunophenotypic features of this lesion.
ABSTRACT
RATIONALE: The current management of lymphoma requires accurate diagnosis and subtyping of de novo lymphoma and of relapsed or refractory lymphoma in known cases. The role of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the clinical management of lymphomas is unclear. OBJECTIVES: To investigate the use of EBUS-TBNA in the diagnosis of de novo and relapsed mediastinal lymphomas. METHODS: A total of 2,256 consecutive patients who underwent EBUS-TBNA in a tertiary center between February 2008 and April 2013 were prospectively evaluated. The diagnostic accuracy and clinical use of EBUS-TBNA in 100 cases of de novo or suspected relapsed mediastinal lymphoma was investigated by comparing EBUS-TBNA diagnosis with the final diagnosis. MEASUREMENTS AND MAIN RESULTS: De novo mediastinal lymphoma was correctly diagnosed by EBUS-TBNA in 45 (88%) of 51 and relapsed lymphoma in 15 (100%) of 15 lymphoma cases. EBUS-TBNA accurately established a diagnosis other than lymphoma in 32 (97%) of 33 patients with suspected lymphoma relapse. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of EBUS-TBNA in the diagnosis of mediastinal lymphoma were 89%, 97%, 98%, 83%, and 91%, respectively. Sensitivity of EBUS-TBNA in subtyping lymphomas into high-grade non-Hodgkin lymphoma, low-grade non-Hodgkin lymphoma, and Hodgkin lymphoma was 90%, 100%, and 79%, respectively. EBUS-TBNA diagnosis was adequate for clinical management in 84 (84%) of 100 cases. CONCLUSIONS: Multimodality evaluation of EBUS-TBNA can be successful in the diagnosis of de novo mediastinal lymphomas and is ideally suited in distinguishing lymphoma relapse from alternative pathologies; it is least sensitive in subtyping Hodgkin lymphoma.
Subject(s)
Endoscopic Ultrasound-Guided Fine Needle Aspiration , Lymphoma/pathology , Mediastinal Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Adult , Aged , Aged, 80 and over , Diagnosis, Differential , Female , Humans , Lymphoma/diagnostic imaging , Male , Mediastinal Neoplasms/diagnostic imaging , Middle Aged , Neoplasm Recurrence, Local/diagnostic imaging , Predictive Value of Tests , Prospective Studies , Sensitivity and SpecificityABSTRACT
Fluorescence in situ hybridisation (FISH) analysis is now widely employed in the diagnosis and risk stratification of a wide range of malignant diseases. While this technique is used successfully with formalin-fixed paraffin-embedded (FFPE) sections from numerous tissue types, FISH analysis of FFPE tissue sections from trephine biopsy specimens has been less widely reported, possibly due to technical limitations relating to the decalcification protocols employed. During the last 4 years FISH analysis has been carried out successfully in 42 out of 55 (76%) consecutive trephine biopsy specimens received as part of the standard diagnostic service at our institution. Samples decalcified using EDTA-based protocols were analysed successfully in 31/31 cases (100%), whereas only 11/24 samples (46%) decalcified using formic acid-based protocols were successful. In our experience, FISH analysis of trephine biopsy specimens is a highly reproducible technique and a very useful adjunctive tool in the diagnostic armoury; however, its use in a standard diagnostic setting relies on the use of EDTA-based decalcification protocols.
Subject(s)
Bone Marrow Diseases/diagnosis , Bone Marrow Examination/methods , Bone Marrow/pathology , Chromosome Aberrations , In Situ Hybridization, Fluorescence , Lymphoproliferative Disorders/diagnosis , Acute Disease , Aged , Biopsy/methods , Bone Marrow Diseases/genetics , Chronic Disease , Decalcification Technique , Female , Formaldehyde , Humans , Leukemia, Myeloid/diagnosis , Leukemia, Myeloid/genetics , Lymphoma, B-Cell/diagnosis , Lymphoma, B-Cell/genetics , Lymphoproliferative Disorders/genetics , Middle Aged , Multiple Myeloma/diagnosis , Multiple Myeloma/genetics , Paraffin Embedding , Tissue Fixation/methodsSubject(s)
Gastrointestinal Stromal Tumors/genetics , Mutation/genetics , Paraganglioma/genetics , Succinate Dehydrogenase/genetics , Adrenalectomy , Adult , Codon, Nonsense , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/surgery , Germ-Line Mutation , Humans , Magnetic Resonance Imaging , Male , Paraganglioma/diagnosis , Paraganglioma/surgery , Tomography, X-Ray ComputedSubject(s)
Eyebrows/pathology , Eyelid Neoplasms/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Optic Nerve Neoplasms/pathology , Orbital Neoplasms/pathology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Skin Neoplasms/pathology , Biomarkers/metabolism , Eyebrows/metabolism , Eyelid Neoplasms/metabolism , Female , Humans , Lymphoma, T-Cell, Cutaneous/metabolism , Magnetic Resonance Imaging , Middle Aged , Optic Nerve Neoplasms/metabolism , Orbital Neoplasms/metabolism , Skin Neoplasms/metabolism , Uveitis, Anterior/pathology , Visual Acuity/physiologySubject(s)
Epithelial Cells/pathology , Hodgkin Disease/pathology , Lymphatic Diseases/pathology , Mediastinal Neoplasms/pathology , Adolescent , Biomarkers , Calbindin 2 , Cell Movement , Desmin/analysis , Diagnosis, Differential , Epithelial Cells/chemistry , Epithelium/pathology , Female , Hodgkin Disease/diagnosis , Humans , Incidental Findings , Lymphatic Metastasis/diagnosis , Mediastinal Neoplasms/diagnosis , Mesothelioma/diagnosis , Models, Biological , Pleural Effusion, Malignant/complications , S100 Calcium Binding Protein G/analysisSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bronchoscopy , Carcinoma/therapy , Chromosomes, Human, Pair 15 , Chromosomes, Human, Pair 19 , Endosonography , Mediastinal Neoplasms/therapy , Pneumonectomy , Radiotherapy, Intensity-Modulated , Translocation, Genetic , Adult , Biopsy, Needle , Carcinoma/diagnosis , Carcinoma/genetics , Chemotherapy, Adjuvant , Humans , Karyotyping , Lymph Node Excision , Male , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/genetics , Neoadjuvant Therapy , Positron-Emission Tomography , Predictive Value of Tests , Radiotherapy, Adjuvant , Treatment OutcomeABSTRACT
AIMS: Because of the clinical difficulty in identifying the early stages of human immunodeficiency virus (HIV) infection, the histopathologist often has to consider the diagnosis of HIV in tissue samples from patients with no previous suspicion of HIV infection. The aim was to investigate the practicality and utility of routine HIV-1 p24 immunohistochemistry on tissue samples received at a London histopathology laboratory. METHODS AND RESULTS: Over a 3-year period, HIV-1 p24 was evaluated immunohistochemically on 123 cases. Of these, 37 (30%) showed positive expression of p24 in lesional follicular dendritic cells (FDCs). Of these 37 cases, 11 were not clinically suspected to be HIV+ and had no prior serological evidence of HIV infection. These cases represented lymph node biopsies, tonsillar and nasopharyngeal biopsies and a parotid excision. In addition to expression on FDCs, in 22 cases (60%), p24 also highlighted mononuclear cells and macrophages. p24 was also useful in confirming the presence of HIV in lymphoid tissue in non-lymphoid organs such as the lung, anus, salivary gland and brain. Immunonegativity occurred in occasional known HIV+ cases, probably related to treatment or tissue processing. CONCLUSIONS: This study confirms the usefulness of this technique in detecting unsuspected HIV infection in lymphoid and non-lymphoid organs on histopathological material and should be part of routine evaluation of lymph nodes and lymphoid tissue in other organs if morphological or clinical features suggest HIV infection.
Subject(s)
Cytodiagnosis/methods , HIV Core Protein p24/analysis , HIV-1/metabolism , Adolescent , Adult , Biopsy , Child , Child, Preschool , Early Diagnosis , Female , HIV Core Protein p24/immunology , HIV-1/genetics , Humans , Immunohistochemistry , Lymph Nodes/chemistry , Lymph Nodes/metabolism , Lymph Nodes/pathology , Lymphoid Tissue/metabolism , Lymphoid Tissue/pathology , Lymphoid Tissue/virology , Male , Middle Aged , Paraffin Embedding , Retrospective StudiesABSTRACT
Diffuse uterine leiomyomatosis (DUL) is a rare entity with an unknown etiopathogenesis. A 24 years old female presented with abdominal discomfort and menorrhagia. Clinical and ultrasonographic examination revealed an enlarged uterus. The hysterectomy specimen showed a symmetrically enlarged uterus with a bosselated external surface. The cut surface showed multiple nodules of varying sizes diffusely involving the myometrium. Microscopically, the nodules were leiomyomas of varying degrees of cellularity. Some of the leiomyomas showed an increased vascularity either in the form of congeries of blood vessels with a lobular arrangement or occasionally as foci of 2-3 vessels. The vessels were surrounded by whorls of spindle cells. On immunohistochemistry the leiomyomas expressed vimentin, smooth muscle actin (SMA), desmin and CD10: the cells whorling around the blood vessels expressed vimentin, SMA and focally desmin and were negative for CD10 and HMB-45. The aim of this paper is to document that CD10 is expressed in diffuse uterine leiomyomatosis and discuss the histogenesis of DUL.